[<sup>68</sup>Ga]Ga-FAPI-04 PET/CT in the evaluation of epithelial ovarian cancer: comparison with [<sup>18</sup>F]F-FDG PET/CT.
prospective_cohort · Level II
Where this comes from
- Record sourced from PubMed, PMID 37526694.
- Also identified by DOI 10.1007/s00259-023-06369-z.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
To compare the efficacy of [<sup>68</sup>Ga]Ga-FAPI-04 PET/CT in primary or recurrent tumors and metastatic lesions of epithelial ovarian cancer (EOC) with that of fluorine-18 fluorodeoxyglucose ([<sup>18</sup>F]F-FDG) PET/CT. Forty-nine patients (median age, 57 years; IQR, 51-66 years) with histologically proven primary or relapsed EOC were enrolled. Participants underwent [<sup>18</sup>F]F-FDG and [<sup>68</sup>Ga]Ga-FAPI-04 PET/CT. The detection rate, diagnostic accuracy, semiquantitative parameters, tumor staging, and clinical management of the tracers were compared. The diagnostic performance of [<sup>18</sup>F]F-FDG and [<sup>68</sup>Ga]Ga-FAPI-04 PET/CT was evaluated and compared using surgical pathology. Differences between methods regarding the peritoneal cancer index (PCI) using preoperative imaging, surgical PCI, and tumor markers (CA125, HE4) were also assessed regarding peritoneal metastases. Among the 49 patients, 28 had primary EOC; 21 had relapsed EOC. [<sup>68</sup>Ga]Ga-FAPI-04 PET/CT outperformed [<sup>18</sup>F]F-FDG PET/CT in detecting peritoneal metastases (96.8% vs. 83.0%; p < 0.001), retroperitoneal (99.5% vs. 91.4%; p < 0.001), and supradiaphragmatic lymph node metastases (100% vs. 80.4%; p < 0.001). Compared with [<sup>18</sup>F]F-FDG, [<sup>68</sup>Ga]Ga-FAPI-04 showed higher SUVmax for peritoneal metastases (17.31 vs. 13.68; p = 0.026) and retroperitoneal (8.72 vs. 6.56; p < 0.001) and supradiaphragmatic lymph node metastases (6.39 vs. 4.20; p < 0.001). Moreover, [<sup>68</sup>Ga]Ga-FAPI-04 PET/CT showed higher sensitivity compared with [<sup>18</sup>F]F-FDG PET/CT for detecting metastatic lymph nodes (80.6% vs. 61.3%; p = 0.031) and peritoneal metastases (97.5% vs. 75.9%; p < 0.001), using surgical pathology as the gold standard. Compared with [<sup>18</sup>F]F-FDG PET/CT, [<sup>68</sup>Ga]Ga-FAPI-04 PET/CT led to an upgrade in 14.3% and 33.3% of treatment-naive and relapse participants, resulting in management changes in 10.7% and 19.0% of the patients, respectively. The median PCI<sub>FAPI</sub> scores were significantly higher than PCI<sub>FDG</sub> (15 vs. 11; p < 0.001) and positively correlated with CA125 and HE4 levels and surgical PCI. [<sup>68</sup>Ga]Ga-FAPI-04 PET/CT achieved higher sensitivity than [<sup>18</sup>F]F-FDG PET/CT in the detection and diagnosis of lymph node and peritoneal metastases, suggesting advantages regarding the preoperative staging of patients with EOC and, thereby, improving treatment decision-making. NCT05034146. Registered February 23, 2021.
Medical subject headings
- Peritoneal Neoplasms
- Quinolines
- Ovarian Neoplasms